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The standard treatment for acute deep venous throm-
bosis (DVT) has been a short course of intravenous
unfractioned heparin (UFH) followed by oral anticoagu-
lants (OAs) for at least 3 months.1,2 Although this treat-
ment has been effective in decreasing mortality and
thromboembolic events, there is a significant risk of hem-
orrhage, and the patient receiving this therapy requires
hospitalization and continuous laboratory monitoring
during initial and long-term treatment. Moreover, it does
not prevent the development of long-term venous insuffi-
ciency and post-thrombotic syndrome (PTS).2 Recent
studies have shown that initial treatment with low molec-
ular weight heparins (LMWHs) is equally or more effec-
tive and safer than UFH,3,4 and LMWHs are now used in
several countries as the initial treatment of choice for most
patients with DVT.5-7
The pharmacologic lysis of a thrombus located in
the deep venous system is an attractive therapeutic
option, because removal of this mass could prevent post-
thrombotic symptoms if lysis occurs before valves are
destroyed.8,9 Fibrinolytic therapy was introduced
because of this, although the risk of acute major bleed-
ing outweighed the potential benefit of a diminished risk
for PTS. Therefore, the routine use of fibrinolytic ther-
apy is currently not defendable.3 The direct or indirect
thrombolytic effect of LMWH has been observed in sev-
eral experimental studies10-13 and is likely to occur in
humans,14-17 which would lead to a reduction of throm-
bus size, thereby preventing venous dysfunction with a
low risk of bleeding.18
Long-term administration of LMWH in the secondary
prophylaxis of thromboembolic events has been used in
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patients who have a high risk of bleeding, in those who
present with complications from OAs, or in those whose
OA therapy could not be monitored easily.18-23 LMWH
has a less-activating effect on osteoclasts than the UFH,
which thereby reduces osteoporosis as a result of long-
term administration.20,24,25 This effectiveness of LMWH
therapy raises the important practical question of whether
LMWH can be used to treat all patients with DVT over
the long term. 
The aim of the current study was to evaluate if
LMWH administration can be used as an alternative to
long-term OAs in patients with DVT, to minimize the
prevalence and severity of early-medium complications
(recurrent thromboembolic events, death, and major
bleeding) and later sequelae (PTS), and to further facili-
tate the outpatient management of DVT.
MATERIALS AND METHODS
Patients. Consecutive symptomatic patients who were
referred to the vascular laboratory in our hospital in whom
lower limb DVT was objectively documented with duplex
scan examination were considered for entry into the study.
Patients were excluded if they were younger than 18 years,
were pregnant, had previous episodes of DVT in the same
limb, had a past complication due to heparin or aceno-
coumarol, received full doses of anticoagulants at the time of
referral, had surgery within the last 5 days, or refused to give
their informed consent. All exclusions were documented.
The study protocol was approved by the Hospital Ethics
Committee. All patients gave their written consent for par-
ticipation in the study according to the Helsinki declaration.
Regimens of treatment. Prefilled syringes were used
containing 10.25 AXa IU/mL of nadroparine calcium
(Fraxiparina; Sanofi  Winthrop, Paris, France). As soon as
the patients were included in the study, a subcutaneous
dose of nadroparine adjusted to body weight (0.1 mL/10
kg) was administered. Because of methodologic require-
ments of the study, all patients were hospitalized during
the initial course of treatment, and a set dose of
nadroparine was subcutaneously administered every 12
hours. Whenever possible, patients were allowed to walk
on the third day; they wore elastic graduated compression
stockings or bandages. After informed consent for the
study was obtained, patients were allocated at random on
the third day to receive an LMWH or an OA. In view of
the nature of the treatments, it was not possible to use a
double-blind design for the study. 
In those patients allocated to the LMWH group, fixed
subcutaneous doses of nadroparine twice a day were con-
tinued at home and were usually administered by the
patients themselves, by relatives, or occasionally by nurses
from the local primary care centers. In patients random-
ized to OA, acenocoumarol (Sintrom; Novartis, Basel,
Switzerland) was administered once a day beginning on
the third day with an initial dose of 4 mg. Further doses
were adjusted to obtain an international normalized ratio
(INR) between 2 and 3. LMWH was given to overlap with
OA and was discontinued when the INR was 2.0 or more
in two consecutive measurements 24 hours apart after at
least 5 days of initial treatment.26 After discharge, those
patients attended the hematologic unit for routine moni-
toring of OA therapy to maintain the INR between 2 and
3. The intensity of oral anticoagulation was expressed as
the percentage of laboratory determinations at the hema-
tologic unit in which a patient had an INR less than 2,
from 2 to 3, or more than 3 with this period calculated
with lineal interpolation.26
Both treatments continued for 3 months and were pro-
longed for 6 months when the DVT affected the iliac or
femoral veins and if the patient had persistent risk factors
for thrombosis or an idiopathic DVT.27 After the third
month, nadroparine was administered once a day at fixed
doses of 0.1 mL/10 kg, whereas the dosage of aceno-
coumarol was set to maintain the INR between 2 and 3.
Duplex scan evaluation. All DVTs were confirmed by
combining B-mode color imaging and Doppler scan mea-
surements. Venous duplex scan examinations were per-
formed with a Philips P-700 scanner (Philips, Einthoven,
The Netherlands) and a 5- or 7.5-MHz probe, depending
on the depth of the veins. We examined deep veins: com-
mon and external iliac veins, the common femoral vein
(CFV), the superficial femoral vein (SFV) along the thigh,
the popliteal vein (PV), and the infrapopliteal vein. Also, the
superficial long and lesser saphenous veins were examined.
The standard findings of partial or complete venous incom-
pressibility and absent or diminished Doppler flow signals
were analyzed.28
For the evaluation of DVT at diagnosis and at 1, 3, 6,
and 12 months of follow-up, an objective and reproducible
quantitative duplex scan score was obtained with the addi-
tion of degrees of thrombi present in the CFV, the SFV,
and the PV with five grades at each segment: 4 points for
complete occlusion (100%), 3 for severe occlusion (61%-
99%), 2 for intermediate occlusion (31%-60%), 1 for slight
thrombosis (1%-30%) and 0 for patency (0%).29 Maximum
value for this score was 12 points (4 × 3). The iliac vein
segment was routinely explored; however, because of the
limitations of duplex scan examinations for establishing the
exact degree of thrombosis into the venous lumen at this
level,30,31 it was not used for calculations of overall scores.
Because measurements of lumen occupation of the
infrapopliteal veins were imprecise, thrombosis at this level
was scored according to location alone; a 1/2 point value
was applied for each thrombosed vein: double tibial (ante-
rior tibial, posterior tibial, peroneal) and muscular veins
(soleal, gastrocnemius). The maximum possible value for
this score was 4 points (1/2 × 8).
The evolution of thrombosis was qualitatively scored
during follow-up with duplex scan examination of the resid-
ual thrombus in the CFV, the SFV, and the PV. Thrombus
scores for both groups at 1, 3, 6, and 12 months were com-
pared with baseline scores, which reflected recanalization
(complete lysis or improvement > 90%), substantial regres-
sion (improvement of 60%-90%), moderate regression (30%-
60%), slight regression (< 30%), unchanged, and
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propagation.32 A repeat duplex scan was performed 24 to 48
hours after standard examination when proximal or distal
thrombus extension (thrombosis in a previously unaffected
venous segment) or worsening (increased degree of throm-
bosis in a previously affected venous segment) was found. 
Additionally, at 6 and 12 months, the duplex scan follow-
up examination included checks on the presence of venous
flow and reflux in deep veins, superficial veins, and com-
municating veins. Reflux was defined as reversed flow with
a velocity of more than 10 cm/s33 or valve closure lasting
more than 2 seconds34 during proximal or distal compres-
sion, which was confirmed with cuff compression. The
duplex scan examinations (diagnosis and follow-up) were
interpreted independently, without knowledge of alloca-
tion to groups to prevent bias.
Surveillance and follow-up. All patients were carefully
examined daily during initial LMWH therapy, with special
emphasis on signs of bleeding or recurrence of DTV. The
following parameters were measured at admission: red
blood cell (RBC) count, hematocrit, hemoglobin level,
white blood cell (WBC) count, platelet count, activated
partial thromboplastin time, prothrombin time, and throm-
bin time. Measurements were repeated on days 3 and 7. 
During surveillance all patients were seen routinely in
our vascular clinic 1, 3, 6, and 12 months after diagnosis
and were instructed to report at once if symptoms or signs
suggestive of recurrent DVT, pulmonary thromboem-
bolism, bleeding, or other complications developed. At
these visits, patients underwent clinical examination; their
limbs were evaluated for tenderness, edema, varicose
veins, hyperpigmentation, or ulceration. The presence of
local complications was documented, and their diameters
were measured. The circumferences of both limbs were
recorded, and duplex scan examination was performed.
RBC count, WBC count, platelet count, activated partial
thromboplastin time, prothrombin time, INR, and throm-
bin time were determined at 1, 3, and 6 months. Patient
compliance was monitored in both groups.
Information was obtained on every subsequent hospi-
tal admission, and the cause of death was documented for
patients who died. The efficacy of treatment was assessed
in terms of the absence or decrease of complications of
DVT or treatment and improvement in clot size.
Complications. The primary outcome was sympto-
matic recurrence or progression of venous thromboem-
bolism documented by duplex scan examination at regular
intervals or earlier if there was any increase in pain, ten-
derness, or edema of the limbs. Recurrence was defined as
the appearance of thrombosis in a previously unaffected
venous segment of the ipsilateral or contralateral leg. In
asymptomatic patients, recurrent DVT was diagnosed in
duplex scan examination follow-up. In patients with clini-
cally suspected pulmonary thromboembolism, the diagno-
sis was confirmed by the presence of a constant
intraluminal filling defect in spiral computed tomography
or conventional angiography.
Bleeding during the study was the second outcome
event. Bleeding was classified as major if it was overt and
was associated with a decrease of 2 g/dL or more in the
hemoglobin level, if it required a blood transfusion of 2
units or more, if it was intracranial or retroperitoneal, or if
the treatment had to be permanently discontinued.26,35,36
All other episodes of bleeding were defined as minor.
Thrombocytopenia was defined as a platelet count below
100,000/µL or a minimum decrease of 40% compared
with the baseline value.35
The final allocation of all potential outcome events,
including deaths, was made by an independent panel of
physicians. The panel included a member of our team who
was not directly involved in the execution of the trial.
Statistical analysis. Analysis was performed with the
SPSS 8.0 statistical package (SPSS, Inc, Chicago, Ill) for
Windows 95 and Microsoft Excel. A P value less than .05
was considered significant. The tests used were difference
of means, the Fisher exact test, and tests for contrast of
proportions. Comparisons for nonparametric distributions
were performed with the Mann-Whitney U test.
RESULTS
Patients. From January 1996 to March 1998, 201
consecutive symptomatic patients with confirmed DVT
were considered to enter the trial. Of these, 43 were
excluded because of age younger than 18 years (1), preg-
nancy (6), previous ipsilateral DVT (10), history of
heparin-induced thrombocytopenia (2), previous treat-
ment with UFH for more than 24 hours (17), lack of staff
(2), surgery within the last 5 days (4), and the refusal of
informed consent (1). Therefore, 158 patients were
included in the study: 81 (51.3%) were assigned to receive
nadroparine, and 77 (48.7%) received acenocoumarol.
There were 69 men and 89 women; ages ranged from
18 to 92 years (mean, 65.7 years). The incidence of vari-
ous predisposing factors did not vary significantly between
the two groups (Table I). The average length of stay was
4.0 days (range, 3-5 days) in the LMWH group and 8.5
days (range, 6-15 days) in the OA group.
For 10 patients (6%), two in the LMWH group and
eight in the OA group, the medication under study was
interrupted before an end point was reached. Nadroparine
was withdrawn in a 66-year-old man immobilized in a
wheelchair with iliofemoral thrombosis after 30 days of
treatment and in an 88-year-old woman with iliofemoral
DVT after 2 months of treatment, because of family and
another physician’s decision. In the OA group, reasons for
treatment interruption were rethrombosis (four patients)
and major bleeding (four patients). Seventy-eight patients
continued treatment for 6 months: 34 in the LMWH
group and 44 in the OA group.
Clinical evaluation. During the study period nearly
all patients showed improvement in clinical DVT symp-
toms. At 12-month follow-up, edema was the most fre-
quent sign found; it was found in 38.3% of the LMWH
group and in 36.4% of the OA group. No clinical evidence
of pathologic fractures or back pain was found during
treatment or follow-up. 
Laboratory findings. No significant alterations in
JOURNAL OF VASCULAR SURGERY
Volume 33, Number 1 López-Beret et al 79
RBC count and WBC count were found. No thrombocy-
topenia was observed during treatment or follow-up. The
mean platelet count in the two groups showed an increase
on the third and seventh days of treatment; it returned to
initial values during the surveillance period. In the hema-
tologic unit, control INR values found were less than 2 in
22.8%, 2 to 3 in 67.8%, and more than 3 in 9.4% of the
OA group.
Complications. The complications observed in both
treatment groups have been summarized in Fig 1 and
Table II.
Recurrent venous thromboembolism. Nine patients,
two (2.5%) of 81 in the LMWH group and seven (9.1%) of
77 in the OA group, had recurrence of DVT; differences
were not significant. DVT recurrence involving the limb
initially affected was found in two patients (22%), and DVT
recurrence in the contralateral limb was found in seven
patients (78%) (P = .0023). No isolated recurrences of
thrombosis were found in duplex scan examinations with-
out clinical signs.
During different phases of the study, thoracic pain
episodes appeared in three patients: a 37-year-old man with
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Fig 1. Complications after long-term treatment of DVT. LMWH, Low molecular weight heparin; NS, not statistically significant; OA,
oral anticoagulant.
Table I. Baseline clinical characteristics of patients
Nadroparine Acenocoumarol
(n = 81) (n = 77) P value
Age—y (mean) 65 (95% CI, 62-69) 66 (95% CI, 63-70) ns
No. < 40 y, 40-70 y, > 70 y 10/34/37 6/31/40 ns
Sex: male/female 31/50 38/39 ns
Side: left/right 46/35 41/36 ns
DVT level:
Iliofemoral DVT 45 39 ns
Femoropopliteal DVT 9 13 ns
Popliteal DVT 13 14 ns
Infrapopliteal DVT 14 11 ns
Relevant associate conditions:
Recent surgery 23 (28.3%)* 19 (24.6%)* ns
Known malignancy 17 (20.9%)* 18(23.3%)* ns
Oral contraceptives 2 (8.3%)† 1 (5.5%)† ns
Hypercoagulability 9 (21.9%)‡ 6 (13.9%)‡
*Total of patients in each group.
†Total of premenopausal women.
‡Total of patients younger than 60 years with idiopathic DVT or younger than 50 years without known permanent risk factors.
DVT, Deep venous thrombosis; ns, not statistically significant.
iliofemoral DVT (on the second day after initial treat-
ment), a 48-year-old obese woman with popliteal DVT (on
the 30th day of LMWH treatment), and a 56-year-old man
with iliofemoral DVT (during the surveillance period, 1
month after the OA therapy was discontinued). Pulmonary
thromboembolism could not be confirmed by means of
computed tomography or pulmonary angiography.
Bleeding complications. No fatal bleeding complica-
tions were found. Major bleeding occurred in four
patients who received OA therapy (5.2%), but did not
occur in the LMWH group. There were four cases of
minor bleeding (4.9%) during long-term LMWH treat-
ment versus none in the OA group. No significant differ-
ence was present. 
Local complications. After 3 months of nadroparine
treatment, nearly all patients had small hematomas, sub-
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Table II. Complications during thrombosis treatment in both groups
Group No. of cases Complications Sex Age (y) Initial DVT Time (d) Predisposing factors
Nadroparine Recurrent DVT (2) Contralateral P-DVT F 88 Iliofemoral 270 Uterine cancer, hormonal
therapy
Ipsilateral FP-DVT M 34 Calf 270 AIDS, hepatitis
Minor bleeding (4) Hematuria M 68 Iliofemoral 8 Prostatectomy
Hematuria M 80 Iliofemoral 60 Carcinoma of bladder
Hematuria F 75 Iliofemoral 8 Carcinomatosis
Blood in stools F 30 Iliofemoral 120 Hemorrhoids, 
granulomatosis colitis
Deaths (9) F 90 Iliofemoral 60 Heart failure
F 78 Iliofemoral 15 Carcinomatosis, ovarian 
cancer
F 75 Iliofemoral 20 Carcinomatosis, uterine 
cancer
F 81 Iliofemoral 45 Carcinomatosis, vaginal 
cancer
F 92 Iliofemoral 50 Heart failure
F 75 Iliofemoral 180 Carcinomatosis, ovarian 
cancer
M 69 Iliofemoral 60 Prostate cancer
M 80 Iliofemoral 120 Bladder cancer, lung 
metastasis
F 50 Femoropopliteal 90 Breast cancer, uterine 
cancer, lung metastasis
Acenocoumarol Recurrent DVT (7) Contralateral IF-DVT M 52 Iliofemoral 270 Unknown for DVT, 
epilepsy
Contralateral IF-DVT F 78 Iliofemoral 60 Ovarian cancer, 
carcinomatosis
Contralateral FP-DV F 56 Iliofemoral 105 Uterine cancer
Contralateral IF-DVT F 78 Iliofemoral 45 Carcinomatosis
Contralateral IP-DVT M 32 Femoropopliteal 180 Activated protein C 
resistance
Contralateral P-DVT F 59 Popliteal 180 Breast cancer, 
chemotherapy
Ipsilateral FP-DVT M 64 Popliteal 60 Stroke, common iliac 
artery occlusion 
Major bleeding (4) Hematuria M 66 Iliofemoral 120 Carcinoma of bladder
Hematuria M 68 Infrapopliteal 8 Partial prostatectomy
Rectorrhage F 70 Iliofemoral 6 Colon cancer
Epistaxis F 56 Iliofemoral 6 Degeneration and 
destruction of turbinates
Deaths (6) F 78 Iliofemoral 90 Carcinomatosis, ovarian 
cancer*
F 76 Iliofemoral 180 Breast cancer, lung 
metastasis
F 70 Iliofemoral 90 Carcinomatosis, colon 
cancer
M 69 Iliofemoral 180 Lung cancer, cerebral 
metastasis
M 78 Iliofemoral 45 Carcinomatosis, colon 
cancer
F 75 Infrapopliteal 150 Breast cancer, lung 
metastasis
*Rethrombosis the second month since randomization, 1 month before death. 
DVT, Deep vein thrombosis; F, female; FP, femoropopliteal; IF, iliofemoral; IP, infrapopliteal; M, male; P, popliteal.
cutaneous nodes, or both at injection sites. A 56-year-old
woman also had local erythema and pruritus after 40 days
of nadroparine administration. 
Mortality. Fifteen patients died during the combined
period of treatment and surveillance: nine in the LMWH
group (11.1%) and six in the OA group (7.8%). This dif-
ference was not significant. No episodes of sudden death
occurred. Thirteen patients with cancer at an advanced
stage died because of the progression of their neoplastic
disease: seven (41.2%) of 17 patients with malignancy in
the LMWH group and six (33.3%) of 18 with cancer in
the OA group. 
Evolution of thrombi. During the surveillance period
556 duplex scan examination were made, 289 in the
LMWH group and 267 in the OA group. Three venous
segments were routinely explored in each limb, and seg-
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Fig 2. Effect of both treatments on the evaluation of thrombosis expressed by quantitative duplex scan score according to DVT level. DVT,
Deep venous thrombosis; LMWH, low molecular weight heparin; NS, not significant; OA, oral anticoagulant; *statistically significant.
mental scores were added to obtain the global scores. The
initial mean clot size score was similar in both groups and
decreased during follow-up in all DVT locations. 
We found that the quantitative duplex scan score
showed statistically significant improvement between
nadroparine therapy and acenocoumarol therapy after
iliofemoral DVT for every checkpoint interval at the first
and third months in femoropopliteal DVT and at the first
month in infrapopliteal DVT. Mean thrombus size
decreased after nadroparine treatment in popliteal DVT
and at the 6th and 12th months in femoropopliteal and
infrapopliteal thrombosis, but no statistical significance
was found with respect to the OA (Fig 2).
Fig 3 shows the quantitative duplex scan in proximal
veins of both groups. A statistically significant decrease in
thrombus size was found in the LMWH group versus the
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Fig 2 Cont’d.
OA group at the 6th and 12th months in the CFV and
during all follow-up in the SFV and the PV. 
Qualitative duplex scan examination showed that at
the end of follow-up, the thrombus recanalization rate was
higher in the LMWH group versus the OA group in the
CFV (63.9% vs 19.3%), the SFV (66.7% vs 14.6%), and the
PV (62% vs 27.5%). This difference was found to be sta-
tistically significant (P < .000; Table III). 
In 22 (2.8%) of the 786 venous segments evaluated at
3, 6, and 12 months, a worsening of the degree of throm-
bosis in a previously affected venous segment that was
improved in its immediately previous status was found: 6
in the CFV (2 [LMWH]/4 [OA]), 7 in the SFV (3
[LMWH]/4 [OA]), and 9 in the PV (4 [LMWH]/5
[OA]) (Table III). These events were clinically asympto-
matic and were unrelated to specific venous segments, the
initial thrombus score, or late development of venous
insufficiency. Recanalization after 1 year of follow-up was
not affected in these cases in any treatment group.
Venous insufficiency. Reflux patterns at 12 months
were similar to those found at the sixth month of follow-
up in superficial, deep, and communicating veins. Table IV
shows rates of venous insufficiency at the end of follow-up
in limb-thrombosed and contralateral veins. 
Incompetence of the long saphenous vein was found
more frequently after iliofemoral thrombosis in both
groups (P = .0130). The rate of incompetent perforating
veins after DVT in the affected limb was higher in the OA
group (P = .0289).
DISCUSSION
Drugs. The DVT was usually treated with a short
course of intravenous UFH followed by an OA for at least
3 months.1 Recently, several trials have shown that initial
treatment with various LMWHs was more efficacious and
safer than treatment with UFH.2,4 To date, the LMWH
long-term efficacy has been evaluated in only a few stud-
ies,6,19-24,37 and it has been compared with standard long-
term OA treatment in only two of them.19,37
In this randomized study we administered nadroparine
calcium, an LMWH produced by nitrous acid depolymer-
ization of UFH with a mean molecular weight around 4.5
d. Several studies have demonstrated that nadroparine was
as or more effective than the adjusted dose of UFH in the
initial treatment of proximal DVT.35,38-42 It was adequate
for outpatient treament,26 it had a lower cost,43 and prob-
ably one daily administration of a more concentrated form
of the drug was allowed.36,44
The complications after the administration of
nadroparine in the initial course of DVT and OAs in long-
term treatment have been revealed in previous trials, but
the exact comparison of reports is not possible because the
drugs used, the dosage schedules, the duration of initial
and long-term treatment, time of surveillance periods, and
methods of evaluation were different. In the review of
medical literature, we found only one case for nadroparine
long-term administration after DVT.22
Our study shows a lower rate of rethrombosis and major
bleeding after long-term treatment with nadroparine versus
acenocoumarol. However, differences were not significant,
perhaps because of the small number of patients (β error).
Although the optimal duration of the anticoagulation
therapy is still a subject of debate, we administered treat-
ment during 3 months and extended it to 6 months in sev-
eral patients with proximal, idiopathic DVT or persistent
risk factors for thrombosis. We maintained the INR
between 2 and 3 when acenocoumarol was administered.3
Our regimen of long-term nadroparine dosage (twice
daily for 3 months and once daily for the following 3
months) is empirical; there are no data regarding the opti-
mal therapeutic range of LMWH dosage during long-term
treatment of thromboembolic disease.
In previous studies, researchers reported one daily
subcutaneous injection of another LMWH preparation
such as dalteparine37 and enoxiparine19 for 3 months after
the first episode of DVT, but several observations suggest
that the failure to achieve an adequate anticoagulant effect
early in the course of anticoagulant treatment can lead to
later recurrences.19,45 We used two daily injections
because probably, levels higher than once a day should be
preferable at this period.
After this treatment period, we further prolonged the
secondary prophylaxis for 3 months in numerous patients;
we used nadroparine once a day. The efficacy and safety of
this LMWH dosage have been shown during long-term
dalteparine administration for up to 70 months.18
However, the two thrombotic recurrences in the LMWH
group occurred 3 months after heparin was stopped, fol-
lowing 6 months of treatment. This may indicate that even
this long period of treatment or this dosage was insuffi-
cient to prevent new thrombotic events in patients with
persistent risk factors for thromboembolic disease.
On the contrary, most recurrences in the OA group
occurred during treatment period, with an INR more than
2. This could mean that new thrombotic episodes begin
before clinical symptoms appear or routine hematologic
laboratory controls are scheduled and could suggest that
OA alone is not an eligible treatment in the acute phase of
thrombotic disease.46
Clinical evaluation showed better results than the
improvement shown by duplex scan examinations. No
thrombus progression was found in duplex scan follow-up
in an unaffected venous segment in absence of sympto-
matic clinical events,47 although the increases in pain and
edema, etc, did not always indicate rethrombosis. 
The bleeding appeared in patients with predisposing
disorders.48,49 The difference in the rate of hemorrhagic
complications could mean that the patients’ control was
better when an LMWH was used.
Nearly all patients who received nadroparine subcuta-
neously twice a day had small ecchymoses, subcutaneous
nodes, or both in the injection site. They were painless and
generally well tolerated by patients. These local
hematomas improved when nadroparine was administered
once a day19 and disappeared about 15 days after subcuta-
neous treatment was stopped.
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Fig 3. Regression of thrombus size according to duplex scan examination in proximal venous segments. LMWH, Low molecular weight
heparin; NS, Not significant; OA, oral anticoagulant; *statistically significant.
Thrombocytopenia was not observed in the follow-
up of this analysis. We found increases in the platelet
count on the third and seventh days after initial treat-
ment with nadroparine, as was previously shown with
another LMWH.50 Unfortunately, we have no explana-
tion for this event, and further study of the causal mech-
anisms is warranted.
In our study, mortality was due to underlying diseases,
not to thromboembolic events.19,22 There were a similar
number of deaths due to advanced malignancy in both
groups. Those results do not substantiate the previous
hypothesis that LMWH administration may exert a favor-
able influence on cancer progression,40,51 even if our reg-
imen of treatment was different.
Overall, the mortality rate was higher than that in
other studies, perhaps because we included all patients
with cancer in the study, independent of their life
expectancy. Except for one patient in the OA group, all
other patients were free of thromboembolic complications
during the last months of their lives. Although neither
treatment prolonged their lives, they did improve their
quality of life while they lived.
Post-thrombotic syndrome. Persistent abnormalities
may occur after acute DVT, which results in PTS52-54
caused by a combination of abnormal microcirculation
and venous hypertension resulting from valvular destruc-
tion and persistent obstruction to outflow.55 The hemo-
dynamic severity of chronic obstruction is complex,
differing markedly with the level and extent of affected
venous segments,55,56 the degree of collateralization, and
the recanalization that may occur. Some degree of reflux
may be present, which also may cause severe symptoms.57
We used conventional duplex scanning to document
the outcome of thrombus itself 9,56,58-60 and the develop-
ment of valvular incompetence9,33,34,61 in the deep and
superficial venous system during follow-up because the
combination of reflux and venous obstruction probably
correlates with ulterior PTS development. In previous
studies with duplex scan sequential examinations of
patients with DVT treated with UFH and OA, it is con-
firmed that clearance of a thrombus is a gradual process
and that recanalization in previously occluded venous seg-
ments occurs over various periods.9,17,47,59-63 We have not
found studies on the long-term evolution of thrombosis
after the administration of nadroparine.
The quantitative/qualitative duplex scan score used in
this study, which is based in previous histologic,29 veno-
graphic,32,64 and duplex thrombosis evaluations,15,65
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Table III. Effect of long-term treatment with nadroparine and acenocoumarol on the evolution of thrombus 
in proximal vein segments after an initial episode of DVT
First month Third month
Venous segment N % A % P value* N % A
CFV
No. duplex scan examinations 45 38 38 34
Recanalization 7 (15.6) 1 (2.6) .0155 13 (34.2) 1
Substantial regression 6 (13.3) 5 (13.2) 7 (18.4) 9
Moderate regression 8 (17.8) 5 (13.2) 9 (23.7) 11
Slight regression 17 (37.8) 17 (44.7) 8 (21.0) 13
Unchanged 7 (15.6) 10 (26.3) 1 (2.6) 0
Worsening† 0 (0.0) 1
SFV
No. duplex scan examinations 51 51 45 46
Recanalization 7 (13.7) 1 (2.0) .0118 13 (28.9) 1
Substantial regression 6 (11.8) 0 (0.0) .0046 9 (20.0) 5
Moderate regression 10 (19.6) 5 (9.8) 9 (20.0) 12
Slight regression 12 (23.5) 19 (37.2) 7 (15.6) 20
Unchanged 16 (31.3) 26 (51.0) .0200 7 (15.6) 8
Worsening† 1 (2.2) 2
PV
No. duplex scan examinations 58 62 53 58
Recanalization 12 (20.7) 3 (4.5) .0040 20 (37.7) 7
Substantial regression 13 (22.4) 3 (4.45) .0020 16 (30.2) 14
Moderate regression 9 (15.5) 8 (13.0) 9 (17.0) 17
Slight regression 11 (18.9) 21 (33.9) .0298 6 (11.3) 14
Unchanged 13 (22.4) 27 (43.5) 2 (3.8) 6
Worsening† 2 (3.8) 3
Figures represent frequency of changes with respect to initial duplex scan score. Values in parentheses are percentages in relation to the
number of partial duplex scan venous examinations.
*Contrast of proportions test.
†Worsening with respect to previous duplex scan score.
A, Acenocoumarol group; CFV, common femoral vein; DVT, deep venous thrombosis; N, nadroparine group; PV, popliteal vein; 
SFV, superficial femoral vein.
shows a higher proportion of venous recanalization (62%-
67%) in proximal venous segments after long-term
nadroparine administration. Regression of thrombus size
also occurred after OA treatment, although to a lesser
degree (15%-27%). The reasons for these results could be
associated to some LMWH characteristics (bioavailability
> 95% after subcutaneous administration, longer half-life,
activity not dose dependent, and low binding to plasma
proteins and to proteins released from activated platelets
and endothelial cells)66 that make it possible to maintain
more stable levels of anticoagulation, which is not always
possible to ensure with an OA, in spite of the performance
of frequent laboratory controls. The significant major
improvement of thrombi in the LMWH group suggests a
thrombolytic effect induced by LMWH,15,17,67 which
probably depends on a modulation of the endothelial cell
of the vessel wall.15
During follow-up we found a worsening of the degree
of thrombosis in some affected vein segments that had
previously improved. This propagation was found inciden-
tally and did not influence the outcome. It may in part
reflect only a progressive occupation of the vein lumen,
caused by increased thrombus adherence and retraction.60
However, symptomatic or asymptomatic extension of
thrombi into previously unaffected segments represents
true propagation of thromboembolic disease.
With color duplex ultrasound scan, it is possible to eval-
uate the lack of vein competency after DVT.8,9,31,55,63,68
This is a result of either destruction of the valve cusp or
incorporation of valves in organizing thrombus.55,60
The valve closure time is the test most used to deter-
mine the degree of reflux within a specific vein seg-
ment.69 The frequency of reflux in the literature depends
heavily on the method used for measuring it and its
quantification. There is no consensus about threshold
value; this may vary between 0.5 seconds and more than
2 seconds.34,53,69,70 In a previous study with healthy per-
sons, reflux in the femoral vein induced by a pneumatic
cuff showed a value of 0.9 seconds.71 We have chosen a
value of 2 seconds to discriminate valve insufficiency
avoiding false-positive results, because the aim of this
study is not to establish the frequency of reflux after
DVT but to compare the rate of venous insufficiency in
two regimens of long-term treatment.
Our findings show a similar frequency of reflux at 6
and 12 months. This confirms the irreversibility of the
venous insufficiency that arises at this time after DVT.61
We found a significantly lower rate of reflux in the
communicating veins of patients in the LMWH group,
probably because very early recanalization may protect
valve function.1 Furthermore, LMWH has an inhibitory
effect on smooth muscle cell proliferation and migra-
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Sixth month 12th month
% P value *N % A % P value N % A % P value
33 36 31
(2.9) .0001 17 (47.2) 5 (15.1) .0010 23 (63.9) 6 (19.3) .0000
(26.5) 9 (25.0) 4 (12.1) 4 (11.1) 9 (29.0) .0322
(32.59) 7 (19.4) 16 (48.4) .0039 5 (13.9) 12 (38.1) .0089
(38.2) 3 (8.3) 8 (24.2) .0348 4 (11.1) 4 (13.0)
(0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
(2.9) 0 (0.0) 1 (3.0) 2 (5.5) 2 (6.4)
42 44 42 41
(2.1) .0001 21 (50.0) 5 (11.4) .0000 28 (66.67) 6 (14.6) .0000
(10.8) 9 (21.4) 15 (34.1) 7 (16.67) 18 (43.9) .0024
(26.1) 6 (14.3) 11 (25.0) 4 (9.52) 9 (22.0)
(43.5) .0011 4 (9.5) 10 (22.7) .0447 2 (4.76) 5 (12.2)
(17.4) 2 (4.7) 3 (6.8) 1 (2.38) 3 (7.3)
(4.3) 2 (4.7) 1 (2.3) 0 (0.0) 1 (2.4)
51 55 50 51
(12.1) .0006 29 (56.9) 13 (23.6) .0001 31 (62.0) 14 (27.5) .0001
(24.1) 14 (27.4) 20 (36.4) 13 (26.0) 23 (45.1) .0203
(29.3) 4 (7.9) 12 (21.8) .0188 4 (8.0) 10 (19.6) .0429
(24.1) .0357 2 (4.0) 8 (14.5) .0262 2 (4.0) 2 (3.9)
(10.3) 2 (4.0) 2 (3.6) 0 (0.0) 2 (3.9)
(5.2) 2 (4.0) 1 0 1
tion.16 We have hypothesized that the reduction of local
inflammatory response could contribute to the reduction
of the fibrotic reaction and thus also residual valvular
lesions and the subsequent appearance of reflux.
Reflux in deep, superficial, and communicating veins
was significantly greater after iliofemoral DVT in both
groups. However, the location and extent of reflux were
not always associated with thrombosis involvement in the
venous segment and are not entirely limited to throm-
bosed vein segments.9,55
The rate of incompetent communicating veins was
greater in the OA group. The fact that this proportion is
reversed in the involved opposite limb suggests that these
findings are associated with the treatment used, rather than
with the existence of previous venous insufficiency at that
level or systemic factors that cause valvular incompetence.67
We thank Rafael Cuena for the randomization, Miguel
Angel Adrados for the oral anticoagulant therapy control,
Raquel López for her statistical support, and Rosa
Bernardo for her assistance in the follow-up of patients.
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